Blair Wade, Cox Christopher
Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania, 19438, USA.
Department of Discovery Chemistry, Merck Research Laboratories, West Point, Pennsylvania, 19438, USA.
F1000Res. 2016 Feb 22;5. doi: 10.12688/f1000research.7665.1. eCollection 2016.
Continued discovery and development of new antiviral medications are paramount for global human health, particularly as new pathogens emerge and old ones evolve to evade current therapeutic agents. Great success has been achieved in developing effective therapies to suppress human immunodeficiency virus (HIV) and hepatitis B virus (HBV); however, the therapies are not curative and therefore current efforts in HIV and HBV drug discovery are directed toward longer-acting therapies and/or developing new mechanisms of action that could potentially lead to cure, or eradication, of the virus. Recently, exciting early clinical data have been reported for novel antivirals targeting respiratory syncytial virus (RSV) and influenza (flu). Preclinical data suggest that these new approaches may be effective in treating high-risk patients afflicted with serious RSV or flu infections. In this review, we highlight new directions in antiviral approaches for HIV, HBV, and acute respiratory virus infections.
持续发现和开发新的抗病毒药物对全球人类健康至关重要，尤其是在新病原体出现以及旧病原体不断进化以逃避现有治疗药物的情况下。在开发抑制人类免疫缺陷病毒（HIV）和乙型肝炎病毒（HBV）的有效疗法方面已经取得了巨大成功；然而，这些疗法并不能治愈疾病，因此目前HIV和HBV药物研发的努力方向是开发长效疗法和/或开发可能导致病毒治愈或根除的新作用机制。最近，针对呼吸道合胞病毒（RSV）和流感的新型抗病毒药物已报道了令人振奋的早期临床数据。临床前数据表明，这些新方法可能对患有严重RSV或流感感染的高危患者有效。在本综述中，我们重点介绍了HIV、HBV和急性呼吸道病毒感染抗病毒方法的新方向。
